LTRN
Lantern Pharma Inc.
Biotechnology
Market Cap$23M
5Y Perf.-66.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LTRN vs ONCO
Revenue, margins, valuation, and 5-year total return — side by side.
ONCO
Onconetix, Inc.
Biotechnology
Market Cap$1M
5Y Perf.-100.0%
LTRN vs ONCO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LTRN | ONCO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $23M | $1M |
| Revenue (TTM) | $0.00 | $815K |
| Net Income (TTM) | $-19M | $-14M |
| Gross Margin | — | 77.6% |
| Operating Margin | — | -21.9% |
| Total Debt | $244K | $49K |
| Cash & Equiv. | $8M | $5M |
LTRN vs ONCO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LTRN
ONCO
| Stock | Feb 22 | May 26 | Return |
|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | 100 | 33.1 | -66.9% |
| Onconetix, Inc. (ONCO) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LTRN vs ONCO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LTRN and ONCO are tied at the top with 3 categories each — the right choice depends on your priorities. Onconetix, Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
LTRN
Lantern Pharma Inc.
The Long-Run Compounder
LTRN carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -86.4% 10Y total return vs ONCO's -100.0%
- 0.9% revenue growth vs ONCO's -67.7%
- 2.9% margin vs ONCO's -17.2%
Best for: long-term compounding
ONCO
Onconetix, Inc.
The Income Pick
ONCO is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.41, yield 30.9%
- Rev growth -67.7%, EPS growth 99.1%
- Lower volatility, beta 1.41, Low D/E 0.3%, current ratio 0.66x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LTRN | 0.9% revenue growth vs ONCO's -67.7% |
| Quality / Margins | LTRN | 2.9% margin vs ONCO's -17.2% |
| Stability / Safety | ONCO | Beta 1.41 vs LTRN's 2.42, lower leverage |
| Dividends | ONCO | 30.9% yield; the other pay no meaningful dividend |
| Momentum (1Y) | LTRN | -53.0% vs ONCO's -98.6% |
| Efficiency (ROA) | ONCO | -68.0% ROA vs LTRN's -97.4%, ROIC -32.8% vs -100.6% |
LTRN vs ONCO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
LTRN vs ONCO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLONCOLAGGINGLTRN
LTRNLantern Pharma Inc.
1leads
ONCOOnconetix, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs LTRNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ONCO1/1
Valuation MetricsMultiples, price ratios, and targets
ONCO2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ONCO6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
LTRN6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ONCO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ONCO and LTRN operate at a comparable scale, with $815,371 and $0 in trailing revenue.
| Metric | LTRNLantern Pharma In… | ONCOOnconetix, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $815,371 |
| EBITDAEarnings before interest/tax | -$20M | -$18M |
| Net IncomeAfter-tax profit | -$19M | -$14M |
| Free Cash FlowCash after capex | -$17M | -$10M |
| Gross MarginGross profit ÷ Revenue | — | +77.6% |
| Operating MarginEBIT ÷ Revenue | — | -21.9% |
| Net MarginNet income ÷ Revenue | — | -17.2% |
| FCF MarginFCF ÷ Revenue | — | -11.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -57.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.1% | +120.9% |
ONCO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ONCO leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | LTRNLantern Pharma In… | ONCOOnconetix, Inc. |
|---|---|---|
| Market CapShares × price | $23M | $1M |
| Enterprise ValueMkt cap + debt − cash | $15M | -$4M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.70x |
| Price / BookPrice ÷ Book value/share | 1.04x | 0.08x |
| Price / FCFMarket cap ÷ FCF | — | — |
ONCO leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ONCO leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
LTRN delivers a -126.0% return on equity — every $100 of shareholder capital generates $-126 in annual profit, vs $-190 for ONCO. ONCO carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to LTRN's 0.01x. On the Piotroski fundamental quality scale (0–9), ONCO scores 5/9 vs LTRN's 2/9, reflecting solid financial health.
| Metric | LTRNLantern Pharma In… | ONCOOnconetix, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -126.0% | -189.8% |
| ROA (TTM)Return on assets | -97.4% | -68.0% |
| ROICReturn on invested capital | -100.6% | -32.8% |
| ROCEReturn on capital employed | -71.4% | -49.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x |
| Net DebtTotal debt minus cash | -$7M | -$5M |
| Cash & Equiv.Liquid assets | $8M | $5M |
| Total DebtShort + long-term debt | $243,657 | $48,774 |
| Interest CoverageEBIT ÷ Interest expense | — | -26.95x |
ONCO leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
LTRN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LTRN five years ago would be worth $1,306 today (with dividends reinvested), compared to $0 for ONCO. Over the past 12 months, LTRN leads with a -53.0% total return vs ONCO's -98.6%. The 3-year compound annual growth rate (CAGR) favors LTRN at -27.3% vs ONCO's -97.2% — a key indicator of consistent wealth creation.
| Metric | LTRNLantern Pharma In… | ONCOOnconetix, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -34.4% | -95.0% |
| 1-Year ReturnPast 12 months | -53.0% | -98.6% |
| 3-Year ReturnCumulative with dividends | -61.5% | -100.0% |
| 5-Year ReturnCumulative with dividends | -86.9% | -100.0% |
| 10-Year ReturnCumulative with dividends | -86.4% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -27.3% | -97.2% |
LTRN leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LTRN and ONCO each lead in 1 of 2 comparable metrics.
Risk & Volatility
ONCO is the less volatile stock with a 1.41 beta — it tends to amplify market swings less than LTRN's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LTRN currently trades 35.5% from its 52-week high vs ONCO's 0.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LTRNLantern Pharma In… | ONCOOnconetix, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.42x | 1.41x |
| 52-Week HighHighest price in past year | $5.74 | $74.30 |
| 52-Week LowLowest price in past year | $1.11 | $0.37 |
| % of 52W HighCurrent price vs 52-week peak | +35.5% | +0.5% |
| RSI (14)Momentum oscillator 0–100 | 47.0 | 28.8 |
| Avg Volume (50D)Average daily shares traded | 694K | 9.4M |
Evenly matched — LTRN and ONCO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
ONCO is the only dividend payer here at 30.89% yield — a key consideration for income-focused portfolios.
| Metric | LTRNLantern Pharma In… | ONCOOnconetix, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | +30.9% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.12 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ONCO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LTRN leads in 1 (Total Returns). 1 tied.
Best OverallOnconetix, Inc. (ONCO)Leads 3 of 6 categories
Loading custom metrics...
LTRN vs ONCO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — LTRN or ONCO?
Over the past 5 years, Lantern Pharma Inc.
(LTRN) delivered a total return of -86. 9%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: LTRN returned -86. 4% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — LTRN or ONCO?
By beta (market sensitivity over 5 years), Onconetix, Inc.
(ONCO) is the lower-risk stock at 1. 41β versus Lantern Pharma Inc. 's 2. 42β — meaning LTRN is approximately 71% more volatile than ONCO relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 1% for Lantern Pharma Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — LTRN or ONCO?
On earnings-per-share growth, the picture is similar: Onconetix, Inc.
grew EPS 99. 1% year-over-year, compared to -1312. 6% for Lantern Pharma Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — LTRN or ONCO?
Lantern Pharma Inc.
(LTRN) is the more profitable company, earning 0. 0% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LTRN leads at 0. 0% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — LTRN or ONCO?
In this comparison, ONCO (30.
9% yield) pays a dividend. LTRN does not pay a meaningful dividend and should not be held primarily for income.
06Is LTRN or ONCO better for a retirement portfolio?
For long-horizon retirement investors, Onconetix, Inc.
(ONCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (30. 9% yield). Lantern Pharma Inc. (LTRN) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONCO: -100. 0%, LTRN: -86. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between LTRN and ONCO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LTRN is a small-cap quality compounder stock; ONCO is a small-cap income-oriented stock. ONCO pays a dividend while LTRN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.